

RECEIVED

DEC 07 2001

TECH CENTER 1600/2800



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

APPLICANTS: Irwin et al. DOCKET NO: 113190/2804
SERIAL NO: 09/865,159 ART UNIT:
FILED: May 24, 2001 EXAMINER:

INVENTION: PSEUDOMONAS TREATMENT COMPOSITION AND METHOD

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

In accordance with the provisions of 37 CFR §1.56, Applicants request that a citation and examination of the references identified below and on the attached PTO-1449 form be made during the course of examination of the above-mentioned application for United States Patent.

By citing the following documents, Applicants do not admit that the documents are prior art and reserve the right to antedate or otherwise demonstrate that the documents are not prior art.

Foreign Patent Documents

PCT Patent Document No. WO 90/11777 dated October 18, 1990

Other Art

Campbell et al, NMR solution structure of the receptor binding domain of *Pseudomonas aeruginosa* pilin strain P1; Int. J. Peptide Protein Res.; vol. 48, pp. 539-552 (1996).

Tripet et al, Engineering a de novo designed coiled-coil heterodimerization domain for the rapid detection, purification and characterization of recombinantly expressed peptides and proteins; Protein Engineering; vol. 9, no. 11; pp. 1029-1042 (1996).

REMARKS

Applicants submit that the references identified above were cited in a European Patent Office Communication ("EPO communication") dated April 25, 2001 regarding a related European patent application. A copy of the EPO communication is submitted herewith.

Applicants note for the record that the *MACDONALD et al* reference which was cited on page 2 of the EPO communication was previously considered during the prosecution of the parent U.S. Patent Application No. 09/329,884 regarding the above-referenced patent application.

Applicants further note for the record that the PCT Publication No. WO 99/57142, which was also cited on page 2 of the EPO communication, was published after the earliest effective filing date of the above-identified patent application and, thus, is precluded as prior art.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayments to Deposit Account No. 02-1818.

Applicants look forward to early and favorable consideration of this matter.

Respectfully Submitted,



(Reg. No. 30,142)


Robert M. Barrett
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690-1135
Tel: (312) 807-4204
Fax: (313) 827-1272
Attorneys for Applicants

16 A1 0590

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT,
(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No. #
113190-064

In Re Application Of: Irwin et al.



Serial No.
09/865,159

Filing Date
May 24, 2001

Examiner

Group 1 Unit

Title: **PSEUDOMONAS TREATMENT COMPOSITION AND METHOD**

RECEIVED
DEC 07 2001
FISH CENTER 1600/2900

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);


OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
113190-064

In Re Application Of: Irwin et al.



Serial No.
09/865,159

Filing Date
May 24, 2001

Examiner

Group Art Unit

TECHCENTER 1600/2900

DEC 07 2001

RECEIVED

Title: PSEUDOMONAS TREATMENT COMPOSITION AND METHOD

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 7/13/01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.6 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Robert J. Buccieri

Typed or Printed Name of Person Mailing Correspondence

Dated: July 13, 2001

Signature

Robert M. Barrett, Esq. (Reg. No. 30,142)
Bell, Boyd & Lloyd LLC
P.O. Box 1135
Chicago, Illinois 60690-1135
Tel: 312/807-4204
Fax: 312/827-1272

CC: